Search company, investor...
Search
AyuVis Research company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

ayuvis.com

Founded Year

2018

Stage

Grant | Alive

Total Raised

$3.85M

Last Raised

$1.8M | 5 mos ago

About AyuVis Research

AyuVis Research is a preclinical stage pharmaceutical company focused on the discovery and development of multi-functional small molecules which boost the body's natural ability to fight disorders associated with inflammation, immunomodulation, and microbial infection. AyuVis compounds stimulate PBMCs to control runaway inflammation or infection and prevent accompanying tissue damage. AyuVis compounds neither activate nor suppress the body's adaptive immune response but rather work through the innate immune system, converting PBMCs into macrophages in a new, alternative therapeutic state. It was founded in 2018 and is based in Fort Worth, Texas.

AyuVis Research Headquarters Location

3500 Camp Bowie Blvd EAD-116J

Fort Worth, Texas, 76107,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AyuVis Research

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AyuVis Research is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

838 items

AyuVis Research Patents

AyuVis Research has filed 2 patents.

The 3 most popular patent topics include:

  • Cannabinoids
  • Clusters of differentiation
  • Cytokines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/2/2019

6/21/2022

Clusters of differentiation, Immune system, Immunology, Cytokines, Interleukins

Grant

Application Date

7/2/2019

Grant Date

6/21/2022

Title

Related Topics

Clusters of differentiation, Immune system, Immunology, Cytokines, Interleukins

Status

Grant

Latest AyuVis Research News

Bronchopulmonary Dysplasia Market to Register Growth at an Extraordinary CAGR of 66.2% by 2032 | DelveInsight

Sep 14, 2022

| DelveInsight News provided by Share this article Share this article The bronchopulmonary dysplasia market is expected to show positive growth in the forecast period (2022–2032) due to the development of well-designed, randomized, controlled non-crossover trials with potential benefits. Moreover, the shortfall of approved therapy might provide suitable space for emerging therapies. LAS VEGAS, Sept. 14, 2022 /PRNewswire/ -- DelveInsight's Bronchopulmonary Dysplasia Market Insights report includes a comprehensive understanding of current treatment practices, bronchopulmonary dysplasia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan]. Key Takeaways from the Bronchopulmonary Dysplasia Market Report DelveInsight estimates that the bronchopulmonary dysplasia market size in the 7MM was approximately USD 0.028 million in 2021. As per our analysis, the total bronchopulmonary dysplasia incident cases in the 7MM were approximately 17K in 2021. Leading bronchopulmonary dysplasia companies such as MEDIPOST Co., Ltd., Airway Therapeutics, Oak Hill Bio Ltd, Meridigen Biotech, AyuVis Research, CHIESI Farmaceutici S.p.A., Velvio, Orphanix, Alveolus Bio Inc, Advent Therapeutics, Trimunocor, The Cell Factory BVBA, Windtree Therapeutics, and others are developing novel bronchopulmonary dysplasia drugs that can be available in the bronchopulmonary dysplasia market in the upcoming years. The promising bronchopulmonary dysplasia therapies in the pipeline include PNEUMOSTEM, AT-100, SHP607, UMC 119 01, AVR 48, NVP-13/-19, AB1000, Aerosolized Vitamin A, CF-MEV-132, AEROSURF, and others. To date, there is no specific cure for BPD, and the focus is on minimizing lung damage and supporting the lung to heal and grow. Discover which therapies are expected to grab major bronchopulmonary dysplasia market share @ Bronchopulmonary Dysplasia Market Report Bronchopulmonary Dysplasia Overview Bronchopulmonary dysplasia (BPD) is a chronic respiratory disease that commonly affects low-birth-weight or premature infants who have received supplemental oxygen or have spent extended periods on a breathing machine (mechanical ventilation), such as infants with acute respiratory distress syndrome. BPD can also occur in older infants with abnormal lung development, an antenatal infection, placental abnormalities (such as preeclampsia), or chorioamnionitis. The most common bronchopulmonary dysplasia cause for a pregnant parent to have their baby delivered prematurely include smoking, alcohol and drug use, infection, chronic health conditions, and others. The bronchopulmonary dysplasia symptoms vary widely, and the most common symptoms include breathing problems, low levels of oxygen in the blood, and others. The clinical evaluation, degree of prematurity, and need for oxygen after a certain age are used for bronchopulmonary dysplasia diagnosis. Bronchopulmonary Dysplasia Epidemiology Segmentation According to DelveInsight estimates, there were approximately 17K bronchopulmonary dysplasia incident cases  in the 7MM in 2021. Among the 7MM countries, the US had the highest incidence of bronchopulmonary dysplasia in 2021. The bronchopulmonary dysplasia market report  proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Incident cases of Bronchopulmonary Dysplasia  Weight-specific cases of Bronchopulmonary Dysplasia  Severity-specific cases of Bronchopulmonary Dysplasia Download the report to understand which factors are driving bronchopulmonary dysplasia epidemiology trends @ Bronchopulmonary Dysplasia Epidemiological Insights Bronchopulmonary Dysplasia Treatment Market  There is no specific cure for BPD; still, the primary goal of bronchopulmonary dysplasia treatment is to prevent further lung damage and to support the infant's lungs so that they can heal and grow. Babies with BPD are frequently treated in a hospital setting and can be closely monitored. Several pharmacologic and non-pharmacologic treatment strategies have been proposed to improve survival, reduce further lung injury, and speed recovery. Infants with mild BPD may not require any special treatment other than a brief period of oxygen, and children with severe BPD may require additional bronchopulmonary dysplasia treatment. Most infants with mild BPD only need oxygen to improve lung capacity and help them breathe, and patients with advanced disease may require oxygen for several months. Noninvasive ventilator support to mechanical ventilation with a tracheostomy are examples of respiratory therapies. These machines either provide nasal continuous positive airway pressure (NCPAP) or bi-level positive airway pressure (Bi-level PAP) (BiPAP). They assist in opening the lungs and working better if the baby's lungs are too small or weak to function normally. Noninvasive ventilation strategies and surfactant administration through thin catheters minimize volutrauma and barotrauma to the developing preterm lung. Current therapies have increased premature infant survival rates. Still, little progress has been made in protecting their undeveloped organs from the trauma of life-saving measures at birth, such as supplemental oxygen and breathing machines. However, new areas of research are yielding novel therapeutic prospects. To know more about the bronchopulmonary dysplasia treatment guidelines, visit @ Bronchopulmonary Dysplasia (BPD) Guidelines Bronchopulmonary Dysplasia Pipeline Therapies and Key Companies OHB-607/TAK-607/SHP607 (Mecasermin Rinfabate): Takeda/Oak Hill Bio CHF5633: Chiesi Farmaceutici S.p.A. The dynamics of the bronchopulmonary dysplasia market are anticipated to change in the coming years. The lack of approved therapies may create an opportunity for emerging therapies such as OHB-607 to gain a significant bronchopulmonary dysplasia market share. Because of exciting new technological advances in the research field, our understanding of BPD's pathophysiology is rapidly improving, opening up new avenues for pursuing therapeutic options in the bronchopulmonary dysplasia market. More research with clearly defined outcomes is needed to develop effective and targeted therapies that provide the best possible care. To evaluate new candidate pharmacological interventions for BPD management, existing models are being refined to better recapitulate pathological processes in affected infants. However, some factors are hindering the growth of the bronchopulmonary dysplasia market. The undiagnosed, unreported cases and the unawareness about the disease remain the primary aspects that strive for the bronchopulmonary dysplasia market growth. Despite significant advances in neonatal intensive care, predicting BPD in preterm babies remains difficult. Moreover, despite the success of animal models in potential testing treatments for BPD, a lack of standardization in approaches and methods makes clinical translation difficult. Furthermore, estimating the exact number of patients suffering from BPD remains difficult due to variability in methodology and definitions of BPD. Uncertain data is a bronchopulmonary dysplasia market risk. Scope of the Bronchopulmonary Dysplasia Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Bronchopulmonary Dysplasia Companies: MEDIPOST Co., Ltd., Airway Therapeutics, Oak Hill Bio Ltd, Meridigen Biotech, AyuVis Research, CHIESI Farmaceutici S.p.A., Velvio, Orphanix, Alveolus Bio Inc, Advent Therapeutics, Trimunocor, The Cell Factory BVBA, Windtree Therapeutics, and others Key Bronchopulmonary Dysplasia Therapies: PNEUMOSTEM, AT-100, SHP607, UMC 119 01, AVR 48, NVP-13/-19, AB1000, Aerosolized Vitamin A, CF-MEV-132, AEROSURF, and others Therapeutic Assessment: Bronchopulmonary Dysplasia current marketed and emerging therapies Bronchopulmonary Dysplasia Market Dynamics:  Bronchopulmonary Dysplasia market drivers and barriers  Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Bronchopulmonary Dysplasia Market Access and Reimbursement Table of Contents

  • When was AyuVis Research founded?

    AyuVis Research was founded in 2018.

  • Where is AyuVis Research's headquarters?

    AyuVis Research's headquarters is located at 3500 Camp Bowie Blvd, Fort Worth.

  • What is AyuVis Research's latest funding round?

    AyuVis Research's latest funding round is Grant.

  • How much did AyuVis Research raise?

    AyuVis Research raised a total of $3.85M.

  • Who are the investors of AyuVis Research?

    Investors of AyuVis Research include National Institute of Child Health and Human Development.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.